Prelude Therapeutics, Inc. (PRLD)
3.23
-0.02
(-0.77%)
USD |
NASDAQ |
Nov 20, 16:00
3.22
-0.01
(-0.31%)
After-Hours: 20:00
Prelude Therapeutics Enterprise Value : 136.04M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 136.04M |
| November 19, 2026 | 138.04M |
| November 18, 2026 | 141.64M |
| November 17, 2026 | 143.24M |
| November 16, 2026 | 150.45M |
| November 13, 2026 | 153.65M |
| November 12, 2026 | 159.25M |
| November 11, 2026 | 180.06M |
| November 10, 2026 | 178.46M |
| November 09, 2026 | 178.46M |
| November 06, 2026 | 165.65M |
| November 05, 2026 | 162.05M |
| November 04, 2026 | 204.06M |
| November 03, 2026 | 180.06M |
| November 02, 2026 | 184.86M |
| October 30, 2026 | 188.06M |
| October 29, 2026 | 205.66M |
| October 28, 2026 | 208.87M |
| October 27, 2026 | 188.06M |
| October 26, 2026 | 173.65M |
| October 23, 2026 | 168.05M |
| October 22, 2026 | 165.65M |
| October 21, 2026 | 169.65M |
| October 20, 2026 | 160.05M |
| October 19, 2026 | 148.85M |
| Date | Value |
|---|---|
| October 16, 2026 | 138.44M |
| October 15, 2026 | 143.24M |
| October 14, 2026 | 136.04M |
| October 13, 2026 | 162.45M |
| October 12, 2026 | 176.86M |
| October 09, 2026 | 188.86M |
| October 08, 2026 | 188.06M |
| October 07, 2026 | 184.06M |
| October 06, 2026 | 182.46M |
| October 05, 2026 | 179.26M |
| October 02, 2026 | 171.25M |
| October 01, 2026 | 180.86M |
| September 30, 2026 | 190.46M |
| September 29, 2026 | 181.73M |
| September 28, 2026 | 177.74M |
| September 25, 2026 | 174.95M |
| September 24, 2026 | 184.12M |
| September 23, 2026 | 209.65M |
| September 22, 2026 | 252.71M |
| September 21, 2026 | 240.75M |
| September 18, 2026 | 254.31M |
| September 17, 2026 | 230.38M |
| September 16, 2026 | 222.41M |
| September 15, 2026 | 226.40M |
| September 14, 2026 | 231.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Q32 Bio, Inc. | -35.16M |
| Intellia Therapeutics, Inc. | 1.159B |
| Twist Bioscience Corp. | 6.520B |
| Beam Therapeutics, Inc. | 1.362B |
| Revolution Medicines, Inc. | 32.42B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.54M |
| Revenue (Quarterly) | 5.647M |
| Total Expenses (Quarterly) | 18.19M |
| EPS Diluted (Quarterly) | -0.1217 |
| Gross Profit Margin (Quarterly) | 93.96% |
| Profit Margin (Quarterly) | -222.1% |
| Earnings Yield | -20.14% |
| Normalized Earnings Yield | -20.14 |